Navigation Links
The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia
Date:6/10/2008

ng from blood cancers.

About Provid Pharmaceuticals Inc.

Provid is a drug discovery service company located in North Brunswick, New Jersey, that provides expert medicinal chemistry support to biotech and pharmaceutical industries, and to government labs, research foundations, and academic groups. The company also uniquely offers experimental due diligence (EXPEDD(TM)) to support decisions by academic technology transfer teams, venture investors, pharma and biotech portfolio management groups. The company has a strategic alliance with iNovacia AB in Stockholm that extends drug discovery capabilities via assay development, screening, and biophysical characterization. For more information, see http://www.providpharma.com.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R), headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, LLS has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, LLS made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call the LLS Information Resource Center (IRC), a call center staffed by master's level social workers and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact: Andrea Greif

914.821.8958
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
6. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
7. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
8. Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
9. Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
10. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
11. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... 21 Cardinal Health, a,global provider of products and ... today announced an order by the New York,Department of ... of,an expanding statewide plan to maintain emergency response readiness, ... Cardinal,Health over the past two years., Cardinal Health ...
... Feb. 21 Human Genome,Sciences, Inc. (Nasdaq: HGSI ... Executive Officer of Trevena, Inc., a privately held,drug discovery ... Directors.,Prior to joining Trevena, Dr. Gowen spent 15 years ... management positions in drug,discovery and development, and led the ...
... Inc.,(Nasdaq: MEDX ) is scheduled to announce ... February 26, 2008 by press release after the,financial ... will host a conference call,and live webcast at ... live, please,dial 1-866-510-0710 (U.S./Canada) or 1-617-597-5378 (international) and,enter ...
Cached Biology Technology:New York Strengthens Emergency Preparedness with Cardinal Health Ventilators 2Human Genome Sciences Appoints Maxine Gowen, Ph.D., to Its Board Of Directors 2Human Genome Sciences Appoints Maxine Gowen, Ph.D., to Its Board Of Directors 3Human Genome Sciences Appoints Maxine Gowen, Ph.D., to Its Board Of Directors 4Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008 2
(Date:12/19/2014)... --  LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ... bring LaunchKey to market in 2015. LaunchKey ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ... flexible and robust – with the clinical data to ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... one of the most common and distressing symptoms cancer ... difficult for health care professionals to accurately assess its ... at Chicago are studying fatigue in cancer patients undergoing ... monitor behaviors such as smoking cessation and alcohol use. ...
... companies aren't touting that slogan. At least not yet. , ... Michigan State University professor of chemical engineering and materials science, ... more efficient and cost-effective. , Dale is internationally known ... plant biomass ?the stems, leaves, stalks and trunks of plants ...
... test a revolutionary treatment for blindness in children has ... The trial, funded by the Department of Health, is ... significant impact on future treatments for eye disease. ... have a condition called Leber’s congenital amaurosis (LCA), which ...
Cached Biology News:Cancer patients monitor fatigue in real time 2First clinical trial of gene therapy for childhood blindness 2
... Goat polyclonal to Cholesterol Oxidase ... / Specificity Cross-reacts with bacteria. Not ... Information Cholesterol oxidases exist as both ... are implicated in bacterial pathogenesis. In addition, ...
Phospho-PERK (Thr980) Antibody...
Goat polyclonal to BACE1 ( Abpromise for all tested applications). entrezGeneID: 23621 SwissProtID: P56817...
Sheep polyclonal to Staphylococcus DNase ( Abpromise for all tested applications). Antigen: Full length native protein (purified)....
Biology Products: